Chromocell Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020
Market Capitalization	7	-	-	-	-
Enterprise Value	4	1	0	-	0
PB Ratio	6.48	-	-	-	-
P/FCF Ratio	-5.23	-	-	-	-
P/OCF Ratio	-5.23	-	-	-	-
EV/Sales Ratio	-	-	-	-	1.21
EV/EBITDA Ratio	-1.38	-0.17	-0.21	-	-0.37
EV/EBIT Ratio	-1.38	-0.17	-0.21	-	-0.37
EV/FCF Ratio	-3.88	-1.19	-0.31	-	-0.07
Debt / Equity Ratio	-	-0.20	-0.15	-	-0.07
Debt / EBITDA Ratio	-	-0.18	-0.23	-	-0.37
Debt / FCF Ratio	-	-1.29	-0.34	-	-0.07
Quick Ratio	1.31	0.01	0.01	0	0
Current Ratio	1.39	0.02	0.02	0	0.02
Interest Coverage	-7.20	-13.23	-16.51	-2352.31	-393.14
Return on Equity (ROE)	222.70%	136.40%	66.60%	16.40%	-
Return on Assets (ROA)	-848.30%	-11824.50%	-8928.30%	-1656.80%	-
Return on Capital (ROIC)	-697.42%	132.58%	73.22%	22.80%	40.58%
Earnings Yield	-122.57%	-	-	-	-
FCF Yield	-38.23%	-	-	-	-
Buyback Yield / Dilution	-322.19%	-193.25%	60.82%	-	-
Total Shareholder Return	-322.19%	-193.25%	60.82%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).